WALNUT CREEK, CA – In what is believed to be a research first, scientists have been able to discern and document the bioavailability of nattokinase in human serum.
The IRB-approved study, entitled “Oral Bioavailability of Nattokinase (NSK-SD®)” by Ng, et al of Machaon Diagnostics, Inc., (Oakland, CA) in conjunction with San Francisco General Hospital Department of Hematology, sought to clarify and quantify the presence of nattokinase in the bloodstream following ingestion.
The researchers gave 11 healthy subjects aged 21 to 65 a single daily dose (2,000 FU) in softgel capsules, providing 100 mg of purified nattokinase (NSK-SD). Each volunteer was subject to blood draws at 0, 2, 4, 8, 12, 24 and 48 hours post ingestion of the supplement; blood draws were measured by ELISA using a rabbit polyclonal anti-nattokinase capture antibody.
The researchers observed a pharmacokinetic pattern for NSK-SO between baseline and 48 hours post-dose, peaking at approximately 13.3 hours (± 2.5 hours) post-dose. Statistically significant increases in detectable serum nattokinase from baseline were documented at time points t = 2 hours through t = 24 hours.
“This is to our knowledge the very first study that demonstrates the nature of the bioavailability of nattokinase,” says Vincent Hackel, President of JBSL-USA. “In addition, the across-the-board bioavailability found in the varied ages of the subjects shows that our NSK-SD may achieve its research-demonstrated efficacy equally for a profound number of people.”
Nattokinase is a serine protease found naturally in natto, the traditional Japanese fermented soybean food. Nattokinase has been shown in a variety of studies to have significant profibrinolytic and antihypertensive effects, and is thus increasingly used as a supplement for the benefit of cardiovascular health. In their abstract, lead author Connie Ng emphasizes, “Little is known regarding the pharmacokinetic and pharmacodynamic properties of this enzyme, and while this study provides important information regarding the bioavailability of nattokinase, further studies are warranted.”
About NSK-SD Nattokinase
The enzyme nattokinase was discovered in 1953 by Dr. K Oshima of Japan when the protease was first isolated from natto, the traditional fermented soy delicacy. In 1995, Japan Bio Science Laboratory scientists perfected a production technique for effective manufacturing of genuine nattokinase for widespread consumption. The company was awarded two Japanese patents and three U.S. patents for its technology in producing its proprietary nattokinase, called NSK-SD®. Research has uncovered properties of NSK-SD that make it an attractive daily supplement to support healthy cardiovascular function. Specifically, studies have shown NSK-SD to promote arterial health via thrombolytic activity, reduce whole blood viscosity, promote normal blood pressure and normal clotting, inhibit platelet aggregation and increase healthy blood circulation.
About Japan Bio Science Laboratory (JBSL)
JBSL, founded in 1974, specializes in the development and manufacturing of functional health supplement and food ingredients anchored by the corporate belief of “the harmony of human beings and Mother Nature,” alongside the quality assurance mission of pursuing the ultimate safety from the viewpoint of the consumer. JBSL currently manufactures and markets NSK-SD, Ashitaba, Sesame Minerals and Biozyme, from its plants in Kyushu and Kyoto, Japan. From its world corporate headquarters in Osaka, Japan, JBSL continues to invest in technology, research and development to provide convenient, safe and effective health ingredients that address modern health concerns.